Background
Methods
Data sources
Statistical analysis
Results
Estimated incidence and mortality
Site
(ICD-10)
| Male | Female | ||
---|---|---|---|---|
New Cases
(Incidence rates)
|
Deaths
(Mortality rates)
|
New Cases
(Incidence rates)
|
Deaths
(Mortality rates)
| |
Colorectal
(C18-C21)
| 37,254 (72.6/78.0) | 13,748 (26.9/31.4) | 36,004 (49.3/55.1) | 14,034 (17.0/20.7) |
Lung
(C33, C34)
| 32,848 (64.4/67.3) | 28,820 (55.9/60.0) | 13,188 (21.8/21.8) | 11,026 (17.0/17.7) |
Breast
(C50)
| 57,231 (104.2/102.2) | 17,592 (26.8/28.4) | ||
Prostate
(C61)
| 58,574 (112.0/117.7) | 11,135 (22.2/29.6) | ||
All cancer sites
(C00-C97 except C44)
| 230,464 (453.6/480.3) | 110,745 (218.7/248.7) | 206,010 (330.8/344.1) | 98,079 (135.2/151.7) |
Year | ||||
---|---|---|---|---|
Site (ICD-10)
| Age group |
2010
|
2015
|
2020
|
Male
| ||||
Colorectal
(C18-C21)
| 0-44 | 860 | 712 | 688 |
45-64 | 11,228 | 12,631 | 13,496 | |
65-84 | 27,750 | 29,063 | 30,634 | |
85+ | 2,490 | 3,423 | 4,189 | |
All ages | 42,328 | 45,829 | 49,007 | |
Lung
(C33, C34)
| 0-44 | 548 | 440 | 426 |
45-64 | 11,425 | 12,782 | 13,552 | |
65-84 | 23,628 | 24,654 | 25,757 | |
85+ | 1,436 | 1,863 | 2,212 | |
All ages | 37,037 | 39,739 | 41,947 | |
Prostate
(C61)
| 0-44 | 0 | 0 | 0 |
45-64 | 16,604 | 18,928 | 20,805 | |
65-84 | 45,974 | 47,542 | 49,823 | |
85+ | 3,257 | 4,434 | 5,406 | |
All ages | 65,835 | 70,904 | 76,034 | |
All cancer sites
(C00-C97 except C44)
| 0-44 | 11,019 | 9,736 | 9,406 |
45-64 | 72,186 | 80,825 | 85,547 | |
65-84 | 163,502 | 171,026 | 179,207 | |
85+ | 12,108 | 16,321 | 19,780 | |
All ages | 258,815 | 277,908 | 293,940 | |
Female
| ||||
Colorectal
(C18-C21)
| 0-44 | 816 | 699 | 681 |
45-64 | 7,627 | 8,488 | 8,799 | |
65-84 | 23,736 | 24,589 | 25,936 | |
85+ | 6,463 | 7,184 | 7,624 | |
All ages | 38,642 | 40,960 | 43,040 | |
Lung
(C33, C34)
| 0-44 | 504 | 410 | 397 |
45-64 | 5,096 | 5,610 | 5,762 | |
65-84 | 7,423 | 7,529 | 7,804 | |
85+ | 969 | 1,066 | 1,125 | |
All ages | 13,992 | 14,615 | 15,088 | |
Breast
(C50)
| 0-44 | 5,678 | 4,763 | 4,632 |
45-64 | 27,317 | 29,800 | 29,960 | |
65-84 | 23,696 | 23,744 | 24,929 | |
85+ | 3,170 | 3,512 | 3,718 | |
All ages | 59,861 | 61,819 | 63,239 | |
All cancer sites
(C00-C97 except C44)
| 0-44 | 15,646 | 13,597 | 13,174 |
45-64 | 66,973 | 73,654 | 75,050 | |
65-84 | 109,926 | 112,281 | 117,904 | |
85+ | 25,098 | 27,762 | 29,391 | |
All ages | 217,643 | 227,294 | 235,519 |
Survival rates
Site
(ICD-10)
| 5-year survival rates | ||
---|---|---|---|
observed
|
relative
|
age-stand. relative
| |
Male
| |||
Colorectal
(C18-C21)
| 49.2 47.2 - 51.0 | 60.4 58.1 - 62.7 | 60.1 54.6 - 65.3 |
Lung
(C33, C34)
| 13.0 11.8 - 14.2 | 15.5 14.1 - 17.0 | 15.4 12.1 - 19.2 |
Prostate
(C61)
| 69.8 68.3 - 71.4 | 87.3 85.3 - 89.2 | 86.0 80.5 - 90.9 |
All cancer sites
(C00-C97 except C44)
| 43.8 43.0 - 44.6 | 52.8 51.8 - 53.7 | 52.2 50.1 - 54.2 |
Female
| |||
Colorectal
(C18-C21)
| 48.1 46.2 - 50.0 | 60.0 57.6 - 62.4 | 61.8 56.4 - 66.6 |
Lung
(C33, C34)
| 15.8 13.6 - 18.2 | 17.8 15.3 - 20.5 | 16.6 11.8 - 22.5 |
Breast
(C50)
| 72.5 71.2 - 73.8 | 81.1 79.6 - 82.5 | 79.6 76.1 - 82.8 |
All cancer sites
(C00-C97 except C44)
| 51.3 50.5 - 52.1 | 59.9 59.0 - 60.9 | 58.3 56.4 - 60.2 |
Prevalence
Site
(ICD-10)
| Number of cancer cases diagnosed over the last | ||
---|---|---|---|
1 year
|
3 years
|
5 years
| |
Male
| |||
Colorectal
(C18-C21)
| 32,400(0.08%) | 79,350(0.20%) | 114,509(0.28%) |
Lung
(C33, C34)
| 20,847(0.05%) | 34,162(0.08%) | 42,242(0.10%) |
Prostate
(C61)
| 56,025(0.14%) | 149,497(0.37%) | 222,254(0.55%) |
All cancer sites
(C00-C97 except C44)
| 202,261(0.50%) | 456,087(1.13%) | 644,302(1.60%) |
Female
| |||
Colorectal
(C18-C21)
| 31,131(0.07%) | 76,988(0.18%) | 113,208(0.27%) |
Lung
(C33, C34)
| 8,750(0.02%) | 15,009(0.04%) | 18,623(0.04%) |
Breast
(C50)
| 55,043(0.13%) | 152,768(0.36%) | 235,779(0.56%) |
All cancer sites
(C00-C97 except C44)
| 189,488(0.45%) | 460,509(1.09%) | 678,955(1.61%) |
Cancer risk
Age-conditional morbidity risk | ||||
---|---|---|---|---|
Site (ICD-10) | Birth to 49 | 50 to 69 | 70 and older | Lifetime morbidity risk |
Male
| ||||
Colorectal
(C18-C21)
| 0.3% | 3.3% | 6.5% | 8.0% |
Lung
(C33, C34)
| 0.3% | 3.1% | 5.1% | 6.9% |
Prostate
(C61)
| 0.1% | 5.5% | 10.2% | 12.4% |
All cancer sites
(C00-C97 except C44)
| 3.3%(1 in 31) | 20.4%(1 in 5) | 42.9% (1 in 2) | 48.5%(1 in 2) |
Female
| ||||
Colorectal
(C18-C21)
| 0.3% | 2.1% | 5.9% | 7.3% |
Lung
(C33, C34)
| 0.2% | 1.1% | 1.4% | 2.5% |
Breast
(C50)
| 2.0% | 5.3% | 4.5% | 10.7% |
All cancer sites
(C00-C97 except C44)
| 4.8%(1 in 21) | 15.5%(1 in 6) | 28.5% (1 in 4) | 40.3%(1 in 2) |
Age-conditional mortality risk | ||||
---|---|---|---|---|
Site (ICD-10)
| Birth to 49 | 50 to 69 | 70 and older | Lifetime mortality risk |
Male
| ||||
Colorectal
(C18-C21)
| 0.1% | 1.0% | 3.1% | 3.3% |
Lung
(C33, C34)
| 0.2% | 2.5% | 4.9% | 6.2% |
Prostate
(C61)
| 0.0% | 0.5% | 3.8% | 3.2% |
All cancer sites
(C00-C97 except C44)
| 1.0%(1 in 103) | 8.3%(1 in 12) | 22.9% (1 in 4) | 25.7%(1 in 4) |
Female
| ||||
Colorectal
(C18-C21)
| 0.1% | 0.5% | 2.8% | 3.0% |
Lung
(C33, C34)
| 0.1% | 0.8% | 1.4% | 2.2% |
Breast
(C50)
| 0.3% | 1.2% | 2.4% | 3.5% |
All cancer sites
(C00-C97 except C44)
| 1.0%(1 in 97) | 5.4%(1 in 18) | 16.2% (1 in 6) | 20.2%(1 in 5) |